CHINARES PHARMA (03320): Tasly Pharmaceutical Group's net profit attributable to shareholders for the first half of the year is 893 million yuan, a year-on-year increase of 15.23%.
China Resources Pharmaceutical (03320) announced that in the first half of 2026, Tasly Pharmaceutical achieved total revenue of RMB 4.201 billion, a year-on-year decrease of 2.03%; net profit attributable to shareholders of the listed company was RMB 893 million, a year-on-year increase of 15.23%; net profit attributable to shareholders of the listed company (after deducting non-recurring gains or losses) was RMB 870 million, a year-on-year increase of 36%; basic earnings per share were RMB 0.6.
CHINARES PHARMA (03320) announced that in the first half of 2026, Tasly Pharmaceutical Group achieved total operating revenue of RMB 4.201 billion, a decrease of 2.03% year-on-year; the net profit attributable to shareholders of the listed company was RMB 893 million, an increase of 15.23% year-on-year; the net profit attributable to shareholders of the listed company (after deducting non-recurring gains or losses) was RMB 870 million, an increase of 36% year-on-year; basic earnings per share were RMB 0.6.
Related Articles
KOWLOON DEV (00034) announced its interim results, with shareholders' profit amounting to HK$131 million, an increase of 4.8% year-on-year.
EAST BUY (01797) announced its annual results, reporting an adjusted profit of approximately 629 million yuan, a year-on-year increase of 262.2%.
Fibocom Wireless Inc. (00638) increased its capital in its holding subsidiary Shanghai Guangyi through a debt-to-equity swap, terminated its equity incentive plan, and sold its equity.
KOWLOON DEV (00034) announced its interim results, with shareholders' profit amounting to HK$131 million, an increase of 4.8% year-on-year.
EAST BUY (01797) announced its annual results, reporting an adjusted profit of approximately 629 million yuan, a year-on-year increase of 262.2%.
Fibocom Wireless Inc. (00638) increased its capital in its holding subsidiary Shanghai Guangyi through a debt-to-equity swap, terminated its equity incentive plan, and sold its equity.
RECOMMEND
